Dapagliflozin (Forxiga®) + Placebo matching Dapaglifolzin
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type2diabetes
Conditions
Type2diabetes, PreDiabetes, Renal Failure
Trial Timeline
Oct 26, 2023 → Sep 30, 2027
NCT ID
NCT06054035About Dapagliflozin (Forxiga®) + Placebo matching Dapaglifolzin
Dapagliflozin (Forxiga®) + Placebo matching Dapaglifolzin is a approved stage product being developed by AstraZeneca for Type2diabetes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06054035. Target conditions include Type2diabetes, PreDiabetes, Renal Failure.
What happened to similar drugs?
0 of 1 similar drugs in Type2diabetes were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06054035 | Approved | Recruiting |
Competing Products
1 competing product in Type2diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Finerenone 20 MG Oral Tablet + Placebo | Bayer | Phase 3 | 44 |